ascopubs.org

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

In a longitudinal clinical study to compare two groups, the primary end point is often the time to a specific event (eg, disease progression, death). The hazard ratio estimate is routinely used to ...
European Medical Journal

GLP 1 Receptor Agonists Reduce Endometrial Cancer Risk

Combined GLP 1 receptor agonists and progestin therapy reduces endometrial cancer risk and hysterectomy rates in women with benign uterine conditions.
Nasdaq

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already ...
ascopubs.org

Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials

We analyzed 54 randomized controlled trials totaling 33,212 patients. The selected outcome was overall survival in 21 (39%) trials. There was evidence of nonproportionality of hazards in 13 (24%) ...
European Medical Journal

Time-of-Day Immunochemotherapy Improves NSCLC Survival

Early Time-of-Day Immunochemotherapy Improved Outcomes. Retrospective signals have suggested that treatment timing may ...
Seeking Alpha

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in ...

The First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab-Containing Regimen Ivonescimab Plus Chemotherapy Demonstrates ...